Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (27010)	12/23/1998 10:09:00 PM
From: roy whitt	Read Replies (1) \| Respond to of 32384

<<I wouldn't spend a nickel for Panretin and Ontak as I think there is no major revenue coming from these two drugs>> then sell........ maybe this is not the stock for you...

To: Arthur Radley who wrote (27010)	12/23/1998 10:44:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< I put in a limit order under the current ask, and after about a 5 minute delay......they gave it to me at my price. >> Congratulations! I hope that you make a bundle on those shares. Hmmm!? What an unselfish comment. <g> I've been bottom fishing for the last two weeks on several stocks, hoping to pick up some stock at bargain basement prices, because of tax selling. Today's drop might have had something to do with Avanir's rejection by the FDA. Since the volume was low for LGND, it probably wasn't a major cause for the drop. "Avanir Pharmaceuticals (AVNR) dropped 63 percent today as a result of the FDA's rejection of its docosanol cream for herpes". The company reported that the FDA issue involved the drugs effectiveness."